Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107208 · ClinicalTrials.gov registry record · Phase 4
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT03107208 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 61 participants.
The verdict
NCT03107208, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the hospital stay. The investigators want to study whether giving the long-acting insulin glargine (Lantus®) early in DKA management (versus after complete resolution of the DKA) helps prevent rebound hyperglycemia and makes the transition to insulin injections easier. Participants will also have the option to wear a continuous glucose monitor (CGM) during the study to help us understand blood glucose control during and after DKA.
Interventions
- DRUG Glargine
- DEVICE Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2021-03-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03107208
The ClinicalTrials.gov registry entry for NCT03107208 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glargine is the first listed.
NCT03107208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03107208 about?
NCT03107208 is a clinical study titled "Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes". A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the hospital stay. The investigators want to study whether giving the long-...
What is the current status of trial NCT03107208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2017-07-21. Estimated completion is 2021-03-13.
What interventions are being tested in trial NCT03107208?
The interventions under investigation include: Glargine (DRUG), Continuous Glucose Monitor (Abbott FreeStyle Libre Pro) (DEVICE).
Who is sponsoring clinical trial NCT03107208?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.